VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Type / Class: Equity / PHARMACEUTCL ETF
Symbol: PPH
Price per share: $103.17
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares: 7,887,542
Total reported value: $712,684,853
% of total 13F portfolios: 0%
Share change: -57,049
Value change: -$3,708,641
Number of holders: 124

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

As of 30 Sep 2025, 124 institutional investors reported holding 7,887,542 shares of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH).

Institutional Holders of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q4	32,083	$3,310,003	-$816,797			$103.17	1
2025 Q3	7,887,542	$712,684,853	-$3,708,641	$40,186,317	$3,587,292	$90.36	124
2025 Q2	7,771,917	$683,617,119	+$174,839,459	$41,446,752	$3,316,092	$87.96	126
2025 Q1	5,807,428	$529,280,107	-$12,990,648	$55,607,526	$1,667,679	$91.13	132
2024 Q4	5,886,585	$507,995,874	+$7,787,762	$4,322,628	$1,251,060	$86.28	137
2024 Q3	5,682,963	$539,851,561	+$86,193,551	$693,719	$1,197,378	$95.03	138
2024 Q2	4,785,937	$437,829,037	+$20,996,709	$4,034,268	$976,940	$91.48	140
2024 Q1	4,528,000	$410,748,432	-$9,142,083	$498,850	$1,632,600	$90.70	134
2023 Q4	104,757	$8,523,707	+$7,302,868			$81.37	3
2023 Q3	4,912,724	$392,393,207	+$18,213,596	$111,804	$551,034	$79.86	96
2023 Q2	4,922,685	$387,758,311	+$6,160,827	$254,064	$779,823	$78.77	98
2023 Q1	4,546,238	$352,923,203	-$177,861,124	$1,016,953	$5,348,387	$77.63	101
2022 Q4	6,551,011	$509,285,983	+$29,764,180	$412,024	$3,288,402	$77.74	108
2022 Q3	6,320,913	$426,534,846	+$120,190,511	$410,000	$7,396,000	$67.24	84
2022 Q2	4,497,093	$345,558,108	+$271,922,798	$1,160,000	$4,834,000	$76.84	88
2022 Q1	876,517	$70,009,375	+$8,992,200	$909,000	$335,000	$79.76	71
2021 Q4	764,244	$58,813,421	-$6,580,803	$1,408,000	$369,000	$76.95	60
2021 Q3	775,015	$56,429,676	+$3,053,751	$2,068,000	$866,000	$72.80	48
2021 Q2	860,970	$62,903,278	-$121,700,461	$731,000	$416,000	$73.07	51
2021 Q1	2,722,067	$187,871,803	+$79,801,400	$41,760,000	$1,118,000	$69.02	50
2020 Q4	1,390,867	$92,672,343	-$36,792,984	$31,676,000	$9,181,000	$66.48	47
2020 Q3	1,950,375	$121,244,606	+$26,978,491	$24,339,000	$361,000	$62.16	48
2020 Q2	1,516,724	$94,426,611	+$34,788,774	$1,619,000	$1,345,000	$62.25	46
2020 Q1	1,060,389	$57,710,237	-$79,299,408	$1,648,000	$2,344,000	$54.39	43
2019 Q4	3,207,226	$205,550,499	+$10,968,131	$1,759,000	$2,611,000	$64.18	47
2019 Q3	2,268,801	$129,242,305	+$52,001,827	$802,000	$819,000	$56.95	42
2019 Q2	952,157	$55,838,403	-$3,054,315	$6,770,000	$1,737,000	$58.67	40
2019 Q1	1,002,023	$60,839,522	-$33,881,043	$473,000	$1,372,000	$60.70	43
2018 Q4	1,560,345	$85,525,178	-$19,786,334	$0	$496,000	$54.79	42
2018 Q3	1,898,981	$122,150,732	-$19,070,496	$1,042,000		$64.34	41
2018 Q2	2,212,062	$130,388,422	+$13,765,277	$920,000	$0	$59.00	47
2018 Q1	1,980,506	$112,507,296	+$23,538,498	$1,651,000	$408,000	$56.82	50
2017 Q4	1,565,374	$92,873,440	-$67,084,976	$339,000	$0	$59.31	48
2017 Q3	2,354,866	$136,016,000	+$67,640,923	$445,000	$312,000	$57.76	45
2017 Q2	1,199,571	$70,841,906	-$41,189,426	$313,000		$59.06	47
2017 Q1	1,898,318	$104,696,270	+$2,251,434			$55.14	47
2016 Q4	1,858,347	$97,627,252	-$64,396,543	$0	$0	$52.51	46
2016 Q3	3,067,732	$176,258,646	+$40,053,184	$454,000	$419,000	$57.46	54
2016 Q2	2,314,947	$135,729,310	+$135,000,075			$58.62	50
2016 Q1	10,828	$623,000	+$623,000			$57.52	2